The Official Website of the Acid Maltase Deficiency Association

It is difficult to say what is impossible for the dreams of yesterday are the hopes of today and the reality of tomorrow. - Robert H. Goddard

Genzyme Pompe Program Update—November 10, 2008

Posted on: November 10, 2008

The US Food and Drug Administration (FDA) held a meeting of its Endocrinologic and Metabolic Drugs Advisory Committee on October 21, 2008 to discuss Genzyme’s Biologics License Application (BLA) for alglucosidase alfa produced at the 2000 L bioreactor scale to treat late-onset Pompe disease in the United States. The Committee voted 16-1 that the Late Onset Treatment Study (LOTS) established the effectiveness of alglucosidase alfa produced at the 2000 L scale for the treatment of patients with late-onset disease.  The majority of the committee members recommended an ‘Accelerated Approval’, which would allow the 2000L to be approved but with the requirement to conduct a verification study of clinical benefit of therapy with alglucosidase alfa.  The committee also recommended that treatment with the 2000 L product should be made available to all patients with late-onset disease, without restrictions based on age. 

Download complete article

Disclaimer: The AMDA does not endorse any of the products, medications, treatments or information reported herein. The website and its contents is intended for informational purposes, only. We strongly advise that you discuss all medications, treatments, and/or products with your physician.

Address: AMDA PO Box 700248
San Antonio, Texas 78270 USA